Cormorant Asset Management »

Eliem Therapeutics shares owned by Cormorant Asset Management

Quarter-by-quarter ownership of Eliem Therapeutics (CLYM) shares owned by Cormorant Asset Management from 13F filings

Historical chart of Cormorant Asset Management investment in Eliem Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Eliem Therapeutics held by Cormorant Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Eliem Therapeutics by Cormorant Asset Management

Quarter filed Position value Share count Share price at filing
2026-06-30 $28M 2.1M 13.04

More positions owned by Cormorant Asset Management

Praxis Precision Medicines I Com New (PRAX)
Bridgebio Oncology Therapeut Com New (BBOT)
Parabilis Medicines
Rapport Therapeutics (RAPP)
Erasca (ERAS)
Edgewise Therapeutics (EWTX)
Eyepoint Com New (EYPT)
Alumis (ALMS)
Abivax Sa Sponsored Ads (ABVX)
Dianthus Therapeutics (DNTH)
Bright Minds Biosciences Com New (DRUG)
Moonlake Immunotherapeutics Class A Ord (MLTX)
Bioage Labs (BIOA)
Oruka Therapeutics (ORKA)
Adlai Nortye Sponsored Ads (ANL)

View all positions for Cormorant Asset Management

Top funds holding Eliem Therapeutics

RA Capital Management
FMR
UBS Group
Braidwell
MPM Oncology Impact Management
Adage Capital Partners GP
Cormorant Asset Management
Frontier Capital Management
T. Rowe Price Associates
Vanguard Capital Management
Citadel Advisors
Redmile Group
Kynam Capital Management
Dr. Jeffrey R. Jay, M.D.
Affinity Asset Advisors

View all funds holding Eliem Therapeutics